Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 1111-1118

  Suenaga, Mitsukuni ^a   Fujimoto, Yoshiya ^b   Matsusaka, Satoshi ^a   Shinozaki, Eiji ^a   Akiyoshi, Takashi ^b   Nagayama, Satoshi ^b   Fukunaga, Yosuke ^b   Oya, Masatoshi ^b   Ueno, Masashi ^b   Mizunuma, Nobuyuki ^a   Yamaguchi, Toshiharu ^b  

^a Department of Gastroenterology ^*  (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Bevacizumab; FOLFOX4; Metastatic colorectal cancer; Perioperative treatment

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANASTOMOSIS LEAKAGE; ANEMIA; ANOREXIA; ARTICLE; ASCENDING COLON; BLEEDING; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COLON CANCER; COLORECTAL CANCER; COLORECTAL SURGERY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; LEUKOPENIA; LIVER METASTASIS; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PEROPERATIVE COMPLICATION; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECTUM CANCER; RECURRENCE FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; SIGMOID; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING; WOUND INFECTION;

EID: 84929402629     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S83952     Document Type: Article

References (18)

1. National Cancer Center, Center for Cancer Control and Information Services. Cancer Statistics in Japan, 2012. Available from: http://ganjoho.jp/public/statistics/backnumber/2012_en.html. Accessed April 19, 2015.
2. Yoshino T, Mizunuma N, Yamazaki K, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled Phase 2 trial. Lancet Oncol. 2012;13:993–1001.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342.
4. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–65.
5. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial. J Clin Oncol. 2005;23:3697–3705.
6. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J Clin Oncol. 2007;26:2013–2019.
7. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2006;25:1539–1544.
8. Robinson S, Manas DM, Pedley I, et al. Systemic chemotherapy and its implications for resection of colorectal liver metastasis. Surg Oncol. 2011;20:57–72.
9. Nordlinger B, Van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20:985–992.
10. Japanese Society for Cancer of the Colon and Rectum. General rules for clinical and pathological studies on cancer of the colon, rectum and anus. Part I. Clinical classification. Surg Today. 1983;13:557–573.
11. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–2351.
12. Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198–2204.
13. de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a Phase 3 randomised controlled trial. Lancet Oncol. 2012;13:1225–1233.
14. FoxTROT Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012;13:1152–1160.
15. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007–1016.
16. Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol. 2014;15:601–611.
17. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:1830–1835.
18. Wong R, Cunningham D, Barbachano Y, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011;22:2042–2048.